Dr. Cicchetti obtained her Ph.D. in neurobiology from Laval University in Québec City (Canada) in 1998. In 2002, she completed a postdoctoral fellowship at Harvard Medical School in the field of cell replacement therapy for neurodegenerative disorders. She is now a professor for the department of Psychiatry & Neurosciences, of Laval University’s Medical School in Québec City. Dr. Cicchetti has published over 80 manuscripts in various high impact journals such as PNAS, Annals of Neurology, Acta Neuropathologica, Trends in Pharmacology, and Brain. She has received numerous awards and distinctions, including the Canadian Institutes of Health Research New Investigator Award (2007-2012), the Fonds de Recherche en Santé du Québec (FRSQ) Junior Research Award (2003-2006 and 2006-2007), Young Investigator Award from NARSAD (2006) and Parkinson Society Canada (2002) and more recently, the prestigious National Researcher award from FRQS (2014-2017), followed by an FRQS research Chair (2017-2021). Three of her recent publications (2014, 2015, 2016) have been awarded most influential papers in the field of Huntington’s disease. She is an active member of several scientific committees and editorial boards.

Our research program is built on 3 distinct themes: 1) to better understand the phenomena that may contribute to the development or the propagation of the pathological aspects found in neurodegenerative diseases (in particular Parkinson’s and Huntington’s) and related-cognitive features; 2) to develop therapeutic strategies that would allow an early or late intervention in the evolution of the disease; 3) to study the mechanisms of action underlying the beneficial and/or detrimental effects of current experimental therapies (cell transplantation and deep brain stimulation) in order to improve these methodologies for the clinic. Our research program is based on translational research, from the animal model to the clinic, with the goal of developing novel therapeutic targets for individuals suffering from Parkinson’s and/or Huntington’s diseases. With this research program, we have developed a considerable expertise in the animal models of these diseases, in imaging/microscopy in small animals, but more importantly in the histopathological analyses of human tissue. Our collaborations with various clinicians provide us invaluable access to human samples (blood, spinal cord, and brain), at times extremely rare (ex.: the brains of transplanted patients). Various pharmaceutical/industrial partners with whom we also collaborate will help us accelerate our findings to tangible clinical applications.

CHUL
2705, boulevard Laurier
T2-07
Québec, Québec
Canada G1V 4G2
127 entries « 1 of 13 »

Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Staffler G, Hayden MR, Southwell AL

Corrigendum to "Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease" [Neurobiology of Disease, 2024 Jan:190:106376]

Journal Article

Neurobiol Dis, 193 , 2024.

| Links:

Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Straffler G, Hayden MR, Southwell AL

Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease

Journal Article

Neurobiol Dis, 190 , 2024.

Abstract | Links:

Tan K, Alpaugh M, Ashton NJ, Chouinard S, Barker RA, Blennow K, Zetterberg H, Cicchetti F, Benedet AL

Plasma GFAP and its association with disease severity in Huntington's disease

Journal Article

J Neurol, 271 (4), 2024.

| Links:

Cardim-Pires TR, de Rus Jacquet A, Cicchetti F

Healthy blood, healthy brain: a window into understanding and treating neurodegenerative diseases

Journal Article

J Neurol, 2024.

Abstract | Links:

Rieux M, Alpaugh M, Salem S, Siddu A, Saint-Pierre M, Denis HL, Rohweder H, Herrmann F, Bazenet C, Lacroix S, Cicchetti F

Corrigendum to "Understanding the role of the hematopoietic niche in Huntington's disease's phenotypic expression: In vivo evidence using a parabiosis model" [Neurobiol Dis. 2023 May;180:106091. doi:10.1016/j.nbd.2023.106091. Epub 2023 Mar 24]

Journal Article

Neurobiol Dis, 187 , 2023.

| Links:

Denis HL, Alpaugh M, Alvarez CP, Fenyi A, Barker RA, Chouinard S, Arrowsmith CH, Melki R, Labib R, Harding RJ, Cicchetti F

Detection of antibodies against the huntingtin protein in human plasma

Journal Article

Cell Mol Life Sci, 80 (2), 2023.

Abstract | Links:

Salem S, Cicchetti F

Untangling the Role of Tau in Huntington's Disease Pathology

Journal Article

J Huntingtons Dis, 12 (1), 2023.

Abstract | Links:

Lepinay E, Cicchetti F

Tau: a biomarker of Huntington's disease

Journal Article

Mol Psychiatry, 28 (10), 2023.

Abstract | Links:

de Rus Jacquet A, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, Beauparlant C, Herrmann L, Saint-Pierre M, Parent M, Droit A, Breton S, Cicchetti F

The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease

Journal Article

Nat Commun, 14 (1), 2023.

Abstract | Links:

Rieux M, Alpaugh M, Salem S, Siddu A, Saint-Pierre M, Denis HL, Rohweder H, Herrmann F, Bazenet C, Lacroix S, Cicchetti F

Understanding the role of the hematopoietic niche in Huntington's disease's phenotypic expression: in vivo evidence using a parabiosis model

Journal Article

Neurobiol Dis, 180 , 2023.

Abstract | Links:

127 entries « 1 of 13 »
Signaler des ajouts ou des modifications

Active projects

  • Premier biomarqueur sanguin de la maladie de Parkinson : de la validation à la commercialisation, from 2022-09-14 to 2024-09-13
  • Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment, from 2021-12-20 to 2024-12-19
  • Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment, from 2020-04-01 to 2025-03-31
  • Redefining PD pathophysiology mechanisms in the context of teterogeneous substantia nigra neuron subtypes, from 2021-09-01 to 2024-10-31

Recently finished projects

  • Crosstalk at the blood-brain barrier: new insights into Parkinson's disease, from 2022-06-30 to 2023-07-31
  • Interrogating induced neuronal cells from Huntington’s disease patients to better understand cognitive impairments, from 2019-11-01 to 2023-06-30
  • Les effets de la cystéamine chez les patients souffrant de la maladie de Huntington : Analyse des données cliniques, from 2023-01-01 to 2023-12-31
  • Targeting the neurovascular unit to prevent disease dissemination and progression, from 2021-01-01 to 2023-03-31
  • Untangling tau contribution to cognitive impairments in Huntington’s disease., from 2019-04-01 to 2024-03-31
Data provided by the Université Laval research projects registery